 8. Has the subject received treatment for leishmaniasis including any medication with pentavalent antimony including sodium stibogluconate Pentostam, meglumine antimoniate Glucantime; amphotericin B including liposomal amphotericin B and amphotericin B deoxycholate; or other medications containing paromomycin administered parenterally or topically or methylbenzethonium chloride MBCL; gentamicin; fluconazole; ketoconazole; pentamidine; miltefosine, azithromycin or allopurinol that was completed within 8 weeks of starting study treatments? 